Formation Bio Valuation, Funding & Investors

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Element Biosciences is a San Diego-based life sciences company building next-generation DNA sequencing instruments. The AVITI platform delivers high-accuracy reads using avidity sequencing chemistry, reducing costs through improved signal-to-noise ratios in surface chemistry and biochemistry. Launched in 2022, it supports workflows from short-read to long-read applications for genomics research. Element Biosciences serves academic labs, biopharma, and clinical sequencing markets worldwide.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.

Enveda Biosciences is a Mountain View-based biotechnology firm using AI to map chemical structures from natural sources for drug discovery. The company has built a database of over 1 million molecules from plants, microbes, and marine organisms, analyzed via mass spectrometry and machine learning. Enveda targets inflammation, oncology, and metabolic diseases, partnering with pharmaceutical companies like Bristol Myers Squibb for lead optimization.

Mammoth Biosciences is a biotechnology company, co-founded by CRISPR pioneer Jennifer Doudna, that develops CRISPR-based tools for diagnostics and gene-editing therapeutics. Its platform is built around compact Cas proteins such as Cas14 and Casφ, which the company applies to in vivo gene editing for genetic and infectious diseases as well as decentralized disease detection. Mammoth has partnered with organizations including Regeneron, GSK, and the NIH, and has received government funding to develop COVID-19 testing technology.

Visby Medical is a diagnostics firm headquartered in Santa Barbara, California, specializing in rapid polymerase chain reaction tests for infectious diseases. Its instrument-free, single-use devices deliver PCR results in under 30 minutes. The company markets FDA-cleared tests for chlamydia, gonorrhea, and trichomoniasis in point-of-care and at-home formats, alongside multiplex assays for COVID-19, influenza A, and influenza B in clinical settings. Visby Medical's platform supports decentralized testing to accelerate disease detection.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

MedGenome is a Bangalore-based genomics company offering next-generation sequencing diagnostics and research services for cancer, metabolic, cardiac, and rare diseases. The firm operates CLIA-certified labs in the United States and India, processing samples for over 500 hospitals and research institutions. Its platform integrates bioinformatics with population-scale data from South Asian genomes, supporting drug discovery partnerships with AstraZeneca and Bristol Myers Squibb in precision medicine initiatives.

Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.